Published in J Infect Dis on December 07, 2012
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One (2015) 1.40
An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog (2013) 1.38
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J Virol (2015) 0.96
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials (2014) 0.93
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis (2013) 0.92
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells. J Immunol (2013) 0.88
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis (2015) 0.82
Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population. PLoS One (2015) 0.78
A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses. PLoS One (2013) 0.78
Are we there yet? The smallpox research agenda using variola virus. PLoS Pathog (2014) 0.77
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects. PLoS One (2016) 0.75
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II. Infect Dis Ther (2017) 0.75
Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol (2003) 5.51
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Complications of smallpox vaccination, 1968. N Engl J Med (1969) 3.08
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B (1978) 2.92
Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med (1987) 2.59
Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med (2005) 2.57
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep (2003) 2.53
[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr (1974) 2.50
The confirmation and maintenance of smallpox eradication. N Engl J Med (1980) 2.46
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol (2005) 2.11
Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol (2004) 2.04
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis (2008) 2.00
Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis (1970) 2.00
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine (2005) 1.94
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest (2008) 1.74
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Myopericarditis following smallpox vaccination. Am J Epidemiol (2004) 1.67
Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol (2004) 1.65
Induction of natural killer cell responses by ectromelia virus controls infection. J Virol (2007) 1.62
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord (2003) 1.41
IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines (2009) 1.36
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine (2009) 1.36
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther (2005) 1.22
Evaluation of smallpox vaccines using variola neutralization. J Gen Virol (2009) 1.21
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine (2009) 1.06
Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol (2006) 0.96
Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination. Am J Med (2009) 0.89
Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am J Cardiol (2005) 0.85
Vaccinia virus infection after sexual contact with a military smallpox vaccinee -Washington, 2010. MMWR Morb Mortal Wkly Rep (2010) 0.78
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med (2011) 4.78
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods (2007) 4.69
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood (2008) 4.34
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One (2008) 4.20
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med (2003) 3.92
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol (2004) 3.43
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med (2008) 2.82
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet (2012) 2.50
Renal disease in an antiretroviral-naïve HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant (2007) 2.45
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest (2005) 2.41
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis (2007) 2.34
Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med (2010) 2.26
Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol (2006) 2.17
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr (2005) 2.15
Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr (2005) 2.09
Maternal education and child nutritional status in Bolivia: finding the links. Soc Sci Med (2005) 2.02
CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med (2002) 2.00
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine (2005) 1.94
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis (2010) 1.91
Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS (2010) 1.87
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest (2008) 1.74
Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. J Acquir Immune Defic Syndr (2008) 1.73
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 1.73
Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol (2007) 1.71
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis (2008) 1.66
Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther (2008) 1.65
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology (2003) 1.59
Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev (2008) 1.55
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics (2012) 1.52
Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS (2006) 1.51
Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet (2009) 1.51
Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet (2002) 1.51
Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother (2006) 1.46
A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology (2008) 1.45
Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog (2007) 1.45
Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol (2010) 1.42
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med (2006) 1.40
Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS (2005) 1.39
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis (2006) 1.37
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine (2009) 1.36
Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr (2008) 1.36
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med (2002) 1.36
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol (2008) 1.31
Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol (2007) 1.29
The aging of the HIV epidemic. Curr HIV/AIDS Rep (2008) 1.27
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS (2011) 1.23
Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era. J Pain Symptom Manage (2011) 1.23
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther (2005) 1.22
Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. Clin Vaccine Immunol (2011) 1.22
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol (2005) 1.22
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics (2012) 1.21
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis (2004) 1.21
Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis (2003) 1.20
Behind the cascade: analyzing spatial patterns along the HIV care continuum. J Acquir Immune Defic Syndr (2013) 1.19
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife (2013) 1.19
Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med (2011) 1.19
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr (2007) 1.17
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther (2007) 1.17
Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr (2009) 1.16
Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol (2010) 1.15
Covered stents for injuries of subclavian and axillary arteries. J Vasc Surg (2003) 1.14
A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS (2004) 1.14
Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet (2012) 1.14
Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med (2013) 1.14
Multidrug-resistant tuberculosis at an HIV testing center in Haiti. AIDS (2006) 1.12
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine (2009) 1.06
Battling AIDS in America: an evaluation of the National HIV/AIDS Strategy. Am J Public Health (2011) 1.06
Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses (2003) 1.04
The transition of adolescent males to first sexual intercourse: anticipated or delayed? Perspect Sex Reprod Health (2002) 1.04
Salvage treatment of histoplasmosis with posaconazole. J Infect (2006) 1.04
An unusual syncytia-inducing human immunodeficiency virus type 1 primary isolate from the central nervous system that is restricted to CXCR4, replicates efficiently in macrophages, and induces neuronal apoptosis. J Neurovirol (2003) 1.04
Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One (2012) 1.04
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genomics (2012) 1.04
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr (2012) 1.04
Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS (2006) 1.03